Literature DB >> 35989893

Bears, beets, rifaximin.

Peter L Wang1, Jennifer A Flemming1,2.   

Abstract

Entities:  

Keywords:  hepatic encephalopathy; rifaximin; TIPS

Year:  2021        PMID： 35989893      PMCID： PMC9235125          DOI： 10.3138/canlivj-2021-0026

Source DB:  PubMed          Journal:  Can Liver J        ISSN： 2561-4444


× No keyword cloud information.
  10 in total

1.  Rifaximin treatment in hepatic encephalopathy.

Authors:  Nathan M Bass; Kevin D Mullen; Arun Sanyal; Fred Poordad; Guy Neff; Carroll B Leevy; Samuel Sigal; Muhammad Y Sheikh; Kimberly Beavers; Todd Frederick; Lewis Teperman; Donald Hillebrand; Shirley Huang; Kunal Merchant; Audrey Shaw; Enoch Bortey; William P Forbes
Journal:  N Engl J Med       Date:  2010-03-25       Impact factor: 91.245

2.  Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

Authors:  Antoni Mas; Juan Rodés; Lourdes Sunyer; Luís Rodrigo; Ramon Planas; Victor Vargas; Lluís Castells; Dolores Rodríguez-Martínez; Conrado Fernández-Rodríguez; Ignasi Coll; Albert Pardo
Journal:  J Hepatol       Date:  2003-01       Impact factor: 25.083

3.  Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.

Authors:  Roberto de Franchis
Journal:  J Hepatol       Date:  2015-06-03       Impact factor: 25.083

4.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.

Authors:  Hendrik Vilstrup; Piero Amodio; Jasmohan Bajaj; Juan Cordoba; Peter Ferenci; Kevin D Mullen; Karin Weissenborn; Philip Wong
Journal:  Hepatology       Date:  2014-07-08       Impact factor: 17.425

5.  The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.

Authors:  Christophe Bureau; Dominique Thabut; Caroline Jezequel; Isabelle Archambeaud; Louis D'Alteroche; Sêbastien Dharancy; Patrick Borentain; Frédéric Oberti; Aurélie Plessier; Victor De Ledinghen; Nathalie Ganne-Carrié; Nicolas Carbonell; Vanessa Rousseau; Agnès Sommet; Jean Marie Péron; Jean Pierre Vinel
Journal:  Ann Intern Med       Date:  2021-02-02       Impact factor: 25.391

6.  Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.

Authors:  O Riggio; A Masini; C Efrati; F Nicolao; S Angeloni; Filippo M Salvatori; M Bezzi; Adolfo F Attili; M Merli
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

Review 7.  Rifaximin: beyond the traditional antibiotic activity.

Authors:  Fiorella Calanni; Cecilia Renzulli; Miriam Barbanti; Giuseppe Claudio Viscomi
Journal:  J Antibiot (Tokyo)       Date:  2014-08-06       Impact factor: 2.649

Review 8.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

Review 9.  TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.

Authors:  Ming Bai; Xing-Shun Qi; Zhi-Ping Yang; Man Yang; Dai-Ming Fan; Guo-Hong Han
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

10.  Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: Low dose vs. full dose rifaximin.

Authors:  Shahid Sarwar; Bushra Muhyuddin; Abdul Aleem; Muhammad Arif Nadeem
Journal:  Pak J Med Sci       Date:  2019 Sep-Oct       Impact factor: 1.088
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.